GLP-1 receptor agonists in older people with type 2 diabetes: safety evidence from the real world
Current RW evidence supports GLP-1RA as a safe therapeutic option for older individuals with T2DM, without age-specific safety signals. Clinical phenotype-driven selection is essential to balance benefits and risks, particularly regarding nutritional status and frailty. Prospective, phenotype-stratified studies with body composition assessment are needed to guide optimal, individualized use in aging populations.
Authors
- Marella Marassi
- Gian Paolo Fadini
Institutions
- University of Padua (IT)
- Institute of Molecular Medicine (IN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1080/14740338.2026.2640982
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00